JP2024514843A5 - - Google Patents
Info
- Publication number
- JP2024514843A5 JP2024514843A5 JP2023561779A JP2023561779A JP2024514843A5 JP 2024514843 A5 JP2024514843 A5 JP 2024514843A5 JP 2023561779 A JP2023561779 A JP 2023561779A JP 2023561779 A JP2023561779 A JP 2023561779A JP 2024514843 A5 JP2024514843 A5 JP 2024514843A5
- Authority
- JP
- Japan
- Prior art keywords
- once
- days
- seizures
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/225,654 US12016829B2 (en) | 2019-10-11 | 2021-04-08 | Pharmaceutical composition and method for treating seizure disorders |
| US17/225,654 | 2021-04-08 | ||
| PCT/IB2022/053271 WO2022215030A1 (en) | 2021-04-08 | 2022-04-07 | Pharmaceutical composition and method for treating seizure disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024514843A JP2024514843A (ja) | 2024-04-03 |
| JP2024514843A5 true JP2024514843A5 (enExample) | 2025-04-14 |
Family
ID=83546168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023561779A Pending JP2024514843A (ja) | 2021-04-08 | 2022-04-07 | 発作性疾患を治療するための医薬組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4319730A4 (enExample) |
| JP (1) | JP2024514843A (enExample) |
| CN (1) | CN117479930A (enExample) |
| AU (1) | AU2022255944A1 (enExample) |
| CA (1) | CA3213953A1 (enExample) |
| MX (1) | MX2023011821A (enExample) |
| WO (1) | WO2022215030A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12186280B2 (en) | 2019-10-11 | 2025-01-07 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| AU2022257344A1 (en) * | 2021-04-12 | 2023-10-26 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010127033A1 (en) * | 2009-04-28 | 2010-11-04 | Alltranz Inc. | Formulations of cannabidiol and methods of using the same |
| EP2424568A1 (en) * | 2009-04-29 | 2012-03-07 | University Of Kentucky Research Foundation | Cannabinoid-containing compositions and methods for their use |
| PT2473475T (pt) * | 2009-08-31 | 2017-08-02 | Zynerba Pharmaceuticals Inc | Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas |
| US20160022627A2 (en) * | 2014-04-18 | 2016-01-28 | Mary's Medicinals LLC | Transdermal cannabinoid patch |
| GB2530001B (en) * | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| BR112017018944A2 (en) * | 2015-03-02 | 2018-05-15 | Afgin Pharma, Llc | method of treating a disease state or condition in humans with a carbinoid drug, and method of treating a disease state or condition in a mammal other than a human with carbinoid drug (s) |
| US9962340B2 (en) * | 2015-06-09 | 2018-05-08 | Life Tech Global, Llc | Device and method for the transdermal delivery of cannabidiol |
| US10272125B2 (en) * | 2015-09-14 | 2019-04-30 | Life Tech Global, Llc | Transdermal delivery of cannabidiol with other active moieties including cannabinoids |
| CN109498606A (zh) * | 2017-09-15 | 2019-03-22 | 汉义生物科技（北京）有限公司 | 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用 |
| JOP20200045A1 (ar) * | 2017-09-19 | 2020-02-27 | Zynerba Pharmaceuticals Inc | كانابيدْيُول تخليقي يتم تناوله عبر الأدمة لعلاج الصرع البؤري لدى البالغين |
| US10821084B2 (en) * | 2018-01-31 | 2020-11-03 | Remy Biosciences, Inc. | Dihydromyricetin compositions |
| WO2021055499A1 (en) * | 2019-09-17 | 2021-03-25 | Zynerba Pharmaceuticals, Inc. | Treatment of behavioral impairment in developmental and epileptic encephalopathy |
| US12186280B2 (en) * | 2019-10-11 | 2025-01-07 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| JP2022551730A (ja) * | 2019-10-14 | 2022-12-13 | パイク セラピューティクス，インコーポレイテッド | カンナビジオールの経皮送達 |
| AU2021392090A1 (en) * | 2020-12-03 | 2023-07-06 | Harmony Biosciences Management, Inc. | Cannabidiol for the treatment of refractory seizures |
-
2022
- 2022-04-07 WO PCT/IB2022/053271 patent/WO2022215030A1/en not_active Ceased
- 2022-04-07 AU AU2022255944A patent/AU2022255944A1/en not_active Abandoned
- 2022-04-07 CN CN202280041014.0A patent/CN117479930A/zh active Pending
- 2022-04-07 JP JP2023561779A patent/JP2024514843A/ja active Pending
- 2022-04-07 EP EP22784263.0A patent/EP4319730A4/en not_active Withdrawn
- 2022-04-07 MX MX2023011821A patent/MX2023011821A/es unknown
- 2022-04-07 CA CA3213953A patent/CA3213953A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023523155A5 (enExample) | ||
| AU2020361741B2 (en) | Transdermal compositions comprising cannabidiol (CBD) for use in the treatment of seizure disorders | |
| US20050187212A1 (en) | Pharmaceutical composition for topical delivery of meloxicam | |
| JP6845162B2 (ja) | ケタミン経皮送達システム | |
| AU2020263285B2 (en) | Continuous delivery of lenalidomide and other immunomodulatory agents | |
| JP6259454B2 (ja) | ジクロフェナク製剤 | |
| JP2022551696A5 (enExample) | ||
| US20040202705A1 (en) | Transdermal administration of huperzine | |
| US20050042271A1 (en) | Transdermal delivery system for alkaloids of aconitum species | |
| RU2004131866A (ru) | Форма для трансэпикутального введения для лечения синдрома усталых ног | |
| JP2022550569A5 (enExample) | ||
| US8852628B1 (en) | Transdermal drug delivery system for diclofenac | |
| JP2016505006A (ja) | レボノルゲストレル及びエチニルエストラジオール用の経皮薬物送達システム | |
| US20240261235A1 (en) | Pharmaceutical Composition And Method For Treating Seizure Disorders | |
| CN115427041A (zh) | 包含羟氯喹和/或氯喹的口服递送系统 | |
| JP2024514843A (ja) | 発作性疾患を治療するための医薬組成物及び方法 | |
| US6896898B1 (en) | Transdermal delivery system for alkaloids of aconitum species | |
| AU2021256454A1 (en) | Transdermal and/or topical delivery system comprising hydroxychloroquine and/or chloroquine | |
| JP2024513961A5 (enExample) | ||
| HK40084062A (en) | Transdermal and/or topical delivery system comprising hydroxychloroquine and/or chloroquine | |
| US20250049821A1 (en) | Pharmaceutical Composition and Method for Treating Seizure Disorders | |
| CN1913903A (zh) | 病毒感染引起的皮肤和粘膜损伤的外用治疗剂 | |
| HRP20170292T1 (hr) | Transdermalni flasteri niske doze s visokim otpuštanjem lijeka |